Cargando…

Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells

The FIP1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRα) fusion oncogene is the driver factor in a subset of patients with hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL). Most FIP1L1-PDGFRα-positive patients respond well to the tyrosine kinase inhibitor (TK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Yingying, Ren, Xiaomei, Ding, Ke, Zhang, Zhang, Wang, Deping, Pan, Jingxuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279382/ https://www.ncbi.nlm.nih.gov/pubmed/25431951

Ejemplares similares

The Conformational Control Inhibitor of Tyrosine Kinases DCC-2036 Is Effective for Imatinib-Resistant Cells Expressing T674I FIP1L1-PDGFRα
por: Shen, Yingying, et al.
Publicado: (2013)

Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin
por: Jin, Yanli, et al.
Publicado: (2014)

Correction to: Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin
por: Jin, Yanli, et al.
Publicado: (2021)

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
por: Helbig, Grzegorz, et al.
Publicado: (2011)

FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia
por: Lierman, Els, et al.
Publicado: (2019)

PB2172: PREVALENCE OF FIP1L1-PDGFRΑ FUSION IN TUNISIAN PATIENTS WITH HYPEREOSINOPHILIA
por: Torkhani, Nermine, et al.
Publicado: (2023)

The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart
por: Haan, Serge, et al.
Publicado: (2015)

Renal thrombotic microangiopathy and FIP1L1/PDGFRα-associated myeloproliferative variant of hypereosinophilic syndrome
por: Langlois, Anne Lyse, et al.
Publicado: (2013)

Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature
por: Boonstra, Pieter A., et al.
Publicado: (2017)

Cardiac Manifestations from Non-FIP1L1-PDGFRα-Associated Hypereosinophilic Syndrome in a 13-Year-Old African American Boy
por: Salm, Cindy M., et al.
Publicado: (2009)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

FIP1L1–PDGFRα-Positive Loeffler Endocarditis—A Distinct Cause of Heart Failure in a Young Male: The Role of Multimodal Diagnostic Tools
por: Varga, Andreea, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ
por: O’Sullivan, Susannah, et al.
Publicado: (2016)

Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl(T315I) inhibitor overcoming acquired imatinib resistance
por: Lu, Xiaoyun, et al.
Publicado: (2017)

Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib
por: Beckmann, Svenja, et al.
Publicado: (2014)

GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo
por: Wang, Yuting, et al.
Publicado: (2020)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib
por: Kim, Dae Sik, et al.
Publicado: (2018)

Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China
por: Qu, Shi-Qiang, et al.
Publicado: (2016)

Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat
por: Wang-Rosenke, Yingrui, et al.
Publicado: (2013)

Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein
por: Li, Xiaoguang, et al.
Publicado: (2017)

The Rab11 effectors Fip5 and Fip1 regulate zebrafish intestinal development
por: Jewett, Cayla E., et al.
Publicado: (2020)

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia
por: Shah, Shilpan, et al.
Publicado: (2014)

Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report
por: Yamamoto, Masayo, et al.
Publicado: (2017)

MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling
por: Park, Jino, et al.
Publicado: (2016)

An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma
por: Yoon, Sorah, et al.
Publicado: (2018)

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer
por: Abe, Michio, et al.
Publicado: (2011)

Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders
por: Mesa, Ruben A
Publicado: (2007)

Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase FIP1L1-PDGFRA-Associated Myeloid Neoplasm With Eosinophilia
por: Jain, Juhi, et al.
Publicado: (2020)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
por: Fischer, Tim, et al.
Publicado: (2017)

PDGFRβ regulates craniofacial development through homodimers and functional heterodimers with PDGFRα
por: Fantauzzo, Katherine A., et al.
Publicado: (2016)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

Chitinase-1 Activity in Serum of Cats with FIP
por: Stranieri, Angelica, et al.
Publicado: (2023)

Suppression of Pyk2 Kinase and Cellular Activities by Fip200
por: Ueda, Hiroki, et al.
Publicado: (2000)

Nck1 Deficiency Impairs Adipogenesis by Activation of PDGFRα in Preadipocytes
por: Haider, Nida, et al.
Publicado: (2018)

Protective Function of Novel Fungal Immunomodulatory Proteins Fip-lti1 and Fip-lti2 from Lentinus tigrinus in Concanavalin A-Induced Liver Oxidative Injury
por: Gao, Yingnyu, et al.
Publicado: (2019)

Impact of Long-Term Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats
por: Tauer, Josephine T., et al.
Publicado: (2015)

Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia
por: Kesely, Kristina R., et al.
Publicado: (2016)

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
por: Tanaka, Atsushi, et al.
Publicado: (2019)

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR
por: Zhou, Yuanfeng, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tauutdho066jsovadns3g6mt5i